Chinless wonder as aesthetic specialist Kythera rises after floating at high end
This article was originally published in Scrip
Aesthetically-focused Kythera Biopharmaceuticals didn't rely on beauty alone to boost its $70.4 million initial public offering on 11 October - the late-stage status of the company's chin-thinning product and previously reported positive Phase III clinical trial results likely appealed to stock buyers who have been wary of earlier-stage investments.
You may also be interested in...
Lilly is planning for growth even beyond the loss of patent protection for Trulicity in 2027. In addition to internal R&D, Smiley said a third of new drugs will come from business development.
Ying Huang was named CEO as his predecessor came under investigation in China and as partner Janssen was getting closer to seeking US FDA approval for its lead CAR-T therapy.
Public Company Edition: 2020 started with two $200m-plus initial public offerings plus five health care-focused special purpose acquisition corporations IPOs. Also, a Pfizer initiative backs three public companies, Fate’s $432m offering led recent FOPOs and Biocon Biologics receives more investment.